Theriva Sells Ribaxamase Portfolio to Biossil for $350K Upfront, Up to $91M in Milestones
TOVX sits 32% above its 52-week low of $0.136 on elevated volume (45× avg).
Summary
Theriva sold SYN-004 (ribaxamase), SYN-007 and certain SYN-006 assets to Biossil Labs for a $350,000 upfront payment, with up to $91 million in contingent regulatory and sales milestones plus a capped royalty. Biossil takes over all future development costs, leaving Theriva with VCN-01 as its lead program.
Key Events · M&A and Partnerships · TOVX
-
Ribaxamase Portfolio Sold to Biossil
Theriva sold all rights to SYN-004 (ribaxamase), SYN-007 and certain SYN-006 assets to Toronto-based Biossil Labs Inc., with closing concurrent with the October 30, 2026 signing.
-
$350K Upfront, Up to $91M Contingent
Biossil paid $350,000 non-refundable at closing; Theriva may receive up to $3 million on first FDA approval and first EMA marketing authorization plus up to $88 million on cumulative worldwide net sales thresholds.
-
Royalty Capped at $250 Million
A low-single-digit royalty on worldwide net sales of the transferred products is capped at $250 million in aggregate, plus a low-double-digit share of license consideration that sits outside the cap.
-
PREV ABR Takes Half of Milestones
An amendment to the 2012 PREV ABR agreement requires a $140,000 closing payment and then 50% of milestone payments, 33⅓% of royalties and 50% of other consideration, capped at $13.0 million in aggregate.
Analysis · TOVX · Life Sciences
Theriva has exited its antibiotic-degrading enzyme franchise entirely, handing development and cost burden to Biossil in exchange for $350,000 cash at closing plus contingent milestones and royalties. Against a roughly $8.7 million market value, the near-term cash is negligible — the real question is whether Biossil can push a paused Phase 1b/2a program and an unapproved asset to market, which is what the up to $3 million regulatory and up to $88 million sales milestones depend on. The filing explicitly warns there is no assurance any milestone will be achieved. Theriva also gave up half of milestone proceeds, a third of royalties and half of other consideration to PREV ABR under a $13.0 million cap, further thinning the economics. What remains is VCN-01, the oncolytic adenovirus, now the lead asset with no partnered revenue behind it.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TOVX was trading at $0.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.14 to $0.49. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.